BR96 sFv PE40

Drug Profile

BR96 sFv PE40

Alternative Names: BMS 191352; BR96 SCIT; SGN 10

Latest Information Update: 27 May 2003

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Seattle Genetics
  • Class Antineoplastics; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 07 Nov 2002 Discontinued - Phase-I for Cancer in USA (unspecified route)
  • 11 Sep 2001 A phase I study has been added to the Cancer pharmacokinetics and adverse events sections
  • 22 Sep 2000 Phase-I clinical trials for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top